Varma Mutual Pension Insurance Co Takes $14.43 Million Position in Boston Scientific Corporation $BSX

Varma Mutual Pension Insurance Co purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 337,981 shares of the medical equipment provider’s stock, valued at approximately $14,425,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific during the fourth quarter valued at $26,000. Sfam LLC bought a new position in shares of Boston Scientific during the fourth quarter valued at $29,000. Finally, Cresta Advisors Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter worth $33,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $50.39 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The company’s fifty day simple moving average is $46.34 and its 200 day simple moving average is $57.62. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. BTIG Research cut their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. TD Cowen decreased their price target on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Needham & Company LLC lowered their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.